Omeros CorporationOMER
▲ PositiveCapitalrelevance
Swung to Q2 profit with net income of $13.23M, driven by YARTEMLEA sales growth of 190%.
Impact on stocks 1
Biotech & Genomic Medicine
Omeros CorporationOmeros Corporation swung to a second-quarter profit, reporting net income of $13.23 million, or $0.18 per share, compared with a net loss of $25.42 million, or $0.43 per share, a year earlier. Net revenue was $28.55 million, driven by YARTEMLEA sales of $32.2 million, which grew 190% from the first quarter of 2026. The company plans to begin enrollment by the end of 2026 in two YARTEMLEA studies, one for hyperinflammatory acute respiratory distress syndrome and another for prophylactic use in pediatric patients with predictably severe transplant-associated thrombotic microangiopathy. Omeros is also initiating a nonclinical study for OMS527 in response to an FDA request and targets a first-in-human Phase 1b trial for OMS805 in late 2027. Shares rose 0.81% to $13.71 in regular trading and surged 15.85% to $15.61 in the overnight market.
Omeros CorporationSwung to Q2 profit with net income of $13.23M, driven by YARTEMLEA sales growth of 190%.